Blood component support in acquired coagulopathic conditions: is there a method to the madness?

Am J Hematol

Division of Transfusion Medicine and Hemostasis, Department of Pathology, UT Southwestern Medical Center, Dallas, Texas 75390-9073, USA.

Published: May 2012


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Acquired coagulopathies are often detected by laboratory investigation in clinical practice. There is a poor correlation between mild to moderate abnormalities of laboratory test and bleeding tendency. Patients who are bleeding due to coagulopathy are often managed with various blood components including plasma, platelets, and cryoprecipitate. However, prophylactic transfusion of these products in a nonbleeding patient to correct mild to moderate abnormality of a coagulation test especially preprocedure is not evidence-based. This article reviews the management of bleeding due to oral anticoagulants and antiplatelet agents, disseminated intravascular coagulation, chronic liver disease, and trauma.

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.23179DOI Listing

Publication Analysis

Top Keywords

mild moderate
8
blood component
4
component support
4
support acquired
4
acquired coagulopathic
4
coagulopathic conditions
4
conditions method
4
method madness?
4
madness? acquired
4
acquired coagulopathies
4

Similar Publications

Dupilumab monotherapy in super-elderly patients with bullous pemphigoid: a retrospective study on long-term efficacy and safety in mild to moderate cases.

J Dermatolog Treat

December 2025

Department of Dermatology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.

Background: Bullous pemphigoid (BP) is a common autoimmune subepidermal bullous disease. Dupilumab, an IL-4/IL-13 inhibitor, represents a novel therapeutic approach for BP, but real-world long-term data in super-elderly patients are limited.

Methods: This retrospective, single-center observational study included super-elderly BP patients (≥80 years) receiving dupilumab monotherapy from September 2022 to September 2024.

View Article and Find Full Text PDF

Ketamine and Esketamine for Late-Life Depression: A Systematic Review of Efficacy, Safety, and Tolerability.

Am J Geriatr Psychiatry

August 2025

Mood Disorder and Psychopharmacology Unit (RS, JKT, CED, RSM), University Health Network, Toronto, Ontario, Canada; Department of Psychiatry, University of Toronnto, Toronto, ON, Canada; Department of Pharmacology and Toxicology, University of Toronto, ON, Canada. Electronic address: roger.mcintyre@

Ketamine has emerged as a promising treatment for major depression, though its efficacy and safety remain incompletely characterized in older adults. This systematic review synthesizes current evidence for ketamine in geriatric depression. A search of PubMed, EMBASE, and PsycINFO was conducted.

View Article and Find Full Text PDF

There is strong evidence supporting the effectiveness of photobiomodulation therapy (PBMT) in improving neuronal damage and enhancing neuropsychological activities. However, there is limited research on the effects of this method on cognitive function and mood disorders. This project aimed to evaluate the potential benefits of PBMT in improving cognitive status and mood disorders in patients with dementia.

View Article and Find Full Text PDF

Background: Little is known about the characteristics of adults with bronchiectasis in France.

Methods: A descriptive cross-sectional study was conducted to describe the characteristics of adults (≥18 years) with clinically-significant bronchiectasis, diagnosed on a combination of respiratory symptoms and CT scan findings, and followed in 18 participating centers. Data on, etiology, lung function, symptoms, microbiology, treatments and quality of life were collected.

View Article and Find Full Text PDF

Objective: To describe the sociodemographic and clinical characteristics of individuals exposed to smoking or biomass smoke and followed at primary health care (PHC) centers across three states in Brazil.

Methods: This was a cross-sectional multicenter study including patients followed at any of four PHC centers in Brazil. Patients ≥ 35 years of age who were smokers or former smokers, or were exposed to biomass smoke were included, the exception being those with physical/mental disabilities and those who were pregnant.

View Article and Find Full Text PDF